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The proto-oncogene Myc was first dis-
covered as the cellular homolog of v-
myc, which was retrovirally captured
from avian genomes and mutated
(Sheiness and Bishop, 1979). When
reintroduced back into host cells, v-myc
acutely promoted cancers in various
avian tissues. The discovery of human
MYC as a target for activation by chro-
mosomal translocation in Burkitt’s lym-
phoma first identified it as a prototypical
oncogene that proved later to be 
commonly involved in many
human cancers (Dalla-
Favera et al., 1982). In 
contrast to activation of
wild-type MYC in solid
tumors, MYC activation in
Burkitt’s lymphoma is medi-
ated via its juxtaposition with
immunoglobulin enhancers.
This predisposes the translo-
cated MYC allele to muta-
tions due to the somatic
hypermutation machinery
that is required for antibody
diversity. Two studies with
large numbers of human
Burkitt’s lymphoma sam-
ples mapped several MYC
mutational hotspots, which
occurred in about 20% of
cases, with a major one cen-
tering around T58 (cited in
Hoang et al., 1995). These
mutations have increased
transforming activity in vitro,
and some mutations are
associated with diminished
Myc’s apoptotic potential.
Intriguingly, the mechanism
by which these mutations
enhance transformation in
vivo was unknown until the
recent study, which utilized a
murine model of lymphoma-
genesis (Hemann et al.,
2005).
The Myc protein consists
of over 430 amino acids with
150 amino-terminal residues comprising
the transactivation domain that encom-
passes two conserved Myc family pro-
tein boxes I and II. Box I contains the
conserved T58 residue (Adhikary and
Eilers, 2005). The carboxy-terminal 90
amino acids comprise the DNA and
dimerization domain that binds an oblig-
ate partner protein, Max. Clues that 
missense mutations in the Myc transacti-
vation domain may be significant arose
from recurrent mutations of the residue
analogous to human T58 and the sur-
rounding region in different, distinct iso-
lates of the v-myc oncogene (Papas and
Lautenberger, 1985). Although muta-
tions affecting T58 and the surrounding
area augment Myc’s transforming
potential, it was unclear whether this
increased transforming potential was
due to increased cell proliferation or
decreased apoptosis (Henriksson et al.,
1993). In fact, several studies suggest
that the inhibitory effect of p107 on Myc
activity may be abrogated by
these mutations (Hoang et
al., 1995). Furthermore, it
was shown that phosphoryla-
tion of T58 leads to the pro-
teasomal degradation of Myc,
and hence mutation of T58
could cause an elevation of
Myc levels that contribute to
tumorigenesis (Salghetti et al.,
1999). It is also notable that
phosphorylation of T58 can be
enhanced by activated Ras,
thereby linking T58 to cooper-
ativity between Myc and Ras
in transformation (Sears et al.,
1999). While these hypothe-
ses are tractable and plausi-
ble, there has been a dearth of
genetic evidence to support
these mechanisms. In vivo
models to test the transform-
ing activities of Myc mutants
were lacking until the study
by Hemann et al. (2005).
The authors sought to
determine the in vivo trans-
forming activities of wild-type
MYC as compared with
Burkitt’s lymphoma-derived
MYC mutants T58A and
P57S (Hemann et al., 2005).
T58 is a target for GSK3β
phosphorylation that is
dependent on the proline
residue at position 57 and
prior phosphorylation of S62;
hence, mutation of P57 also
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Increased wild-type MYC expression occurs frequently in human cancers, except in Burkitt’s lymphoma, where the translo-
cated MYC allele is frequently mutated at several hotspots, including a major one at threonine-58. Acute MYC expression
increases p53 or ARF levels and induces apoptosis, and previous transgenic animal studies revealed frequent inactivating
mutations of p53 or p19ARF in transgenic Myc-induced lymphomas. Lowe and coworkers (Hemann et al., 2005) demon-
strate that wild-type MYC can also trigger apoptosis by inducing Bim, which neutralizes Bcl-2. In contrast, the MYC point
mutants failed to induce Bim, promoting murine lymphomas that escaped both wild-type p53 and p19ARF, and in doing so,
evaded apoptosis.
Figure 1. Mechanisms for escaping MYC-induced apoptosis
A: Acute or ectopic activation of Myc induces target genes involved
in cell growth and cell cycle progression, but the activation of ARF,
p53, and Bim (which inhibits Bcl-2) results in apoptosis or cell cycle
arrest. The AND logic gate depicts the requirement of at least two
signals, ARF-p53 AND Bim, to trigger apoptosis. 
B: Wild-type Myc induces lymphomagenesis coordinately with the
inactivation of ARF or p53. 
C: Myc mutants derived from Burkitts lymphoma fail to activate Bim
and hence promote lymphomagenesis despite the presence of wild-
type p53 or ARF.
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abrogates T58 phosphorylation (Hoang
et al., 1995). Irradiated recipient mice
were transplanted with murine fetal liver-
derived hematopoietic progenitors that
express retroviral vectors that harbor
wild-type or mutant MYC transgenes.
Animals transplanted with hematopoietic
cells containing MYC mutants rapidly
succumbed to lymphomas, whereas
those receiving cells with wild-type MYC
had a delayed onset of lymphomas.
Retrovirally transduced cells with wild-
type or MYC point mutants demonstrat-
ed similar proliferative potential as
determined by BrdU uptake; however,
apoptosis was significantly diminished
with cells expressing MYC mutants. The
authors examined specifically the
expression of p19ARF and p53 in the
mutant MYC-induced tumors, since it
was previously demonstrated that these
checkpoint genes are frequently mutated
in MYC-induced lymphomas (Eischen et
al., 1999). Unlike the wild-type MYC
tumors, the mutant MYC tumors had
wild-type p19ARF and p53, but the
expression of Bim was markedly dimin-
ished. To test the significance of the
inability of Myc mutants to induce Bim,
which binds to and inactivates Bcl-2, the
authors measured the ability of wild-type
and mutant Myc to induce apoptosis in
wild-type and knockout Bcl-2 murine
embryo fibroblasts (MEFs). In wild-type
Bcl-2 cells, wt Myc induced higher levels
of apoptosis than the Myc mutants.
However, in Bcl-2 null MEFs, Myc
mutants induce a similar level of apopto-
sis as wild-type Myc.These observations
support the hypothesis that diminished
activation of Bim by Myc mutants causes
a decrease in Myc-mediated apoptosis.
Additional experiments using Bim−/−
stem cells revealed that wild-type and
Myc mutants develop lymphomas at sim-
ilar rates. These observations suggest
that the inability of Myc mutants to
induce Bim contributes to their enhanced
tumorigenicity. However, the mechanism
by which Myc activates Bim was not
defined in this study.
To determine the clinical significance
of their findings, the authors demonstrate
a differential level of Bim expression in
human Burkitt’s lymphomas bearing
wild-type versus mutant MYC alleles.
Indeed, Bim expression was virtually
absent in lymphomas with MYC Box I
mutations. The authors also noted from
the literature that Burkitt’s lymphomas
with p53 mutations appear devoid of
coding sequence mutations in MYC.
These correlations support the key
observation in this study that Burkitt’s
lymphoma-derived MYC Box I mutations
increase oncogenicity by diminishing the
level of apoptosis through the failure to
activate Bim.
The ability of endogenous Myc to
stimulate cell proliferation and of ectopic,
pathologic Myc levels to transform cells
is linked to their target transcriptomes
(Adhikary and Eilers, 2005). The expres-
sion of endogenous MYC is tightly regu-
lated, such that its expression is highly
sensitive to external cellular cues, as
well as internal homeostatic mecha-
nisms. In contrast, ectopic Myc expres-
sion not only affects the physiological
Myc-responsive transcriptome, but also
acutely induces a set of genes that
respond to pathophysiologic levels of
Myc. It stands to reason that Myc should
be tightly regulated, but mechanisms to
keep cells with deregulated Myc in check
must also evolve to protect the host
organism from sustaining lethal onco-
genic events. As such, acute activation of
Myc in normal cells triggers cell growth
arrest or apoptosis through the induction
of p53 or p19ARF (Eischen et al., 1999).
Hemann et al. demonstrate that in addi-
tion to these downstream events, wild-
type, but not mutant, Myc induces Bim to
trigger apoptosis (Figure 1), confirming.a
previous report (Egle et al., 2004). Their
study further shows that mutant Myc
could induce lymphomagenesis in the
presence of wild-type p53 and p19ARF,
suggesting that Myc can trigger apopto-
sis through multiple independent mecha-
nisms. Furthermore, their observations
suggest that these independent path-
ways must be integrated and a cumula-
tive threshold effect reached to trigger
apoptosis. Hence, mutations of p53 or
p19ARF collaborating with wild-type
Myc, or mutations of Myc that fail to
induce Bim, appear sufficient for initiat-
ing lymphomagenesis.
It should be noted that in addition to
the suppression of Myc-induced apopto-
sis by Myc Box I mutations, Myc must
also activate genes that are required for
tumorigenesis (Adhikary and Eilers,
2005). The spectrum of genes induced
by Myc involves almost all known cellular
functions, with overrepresentation of
genes that regulate the cell cycle and
carbohydrate and nucleotide metabo-
lism, as well as ribosomal and mitochon-
drial biogenesis. Although Lowe and
coworkers attributed higher transforming
potencies of Myc mutants in vivo to
diminished apoptosis, they did not direct-
ly assess whether other tumorigenic
events such as adaptation to the tumor
microenvironment or angiogenesis could
be affected by Myc Box I mutations.
Nonetheless, their demonstration of a
differential effect between wild-type and
mutant Myc suggests that alterations in
apoptosis play a central role in the activi-
ty of Myc mutants.
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